IMPROVED SURVIVAL AFTER A MEDIAN FOLLOW-UP OF 6 YEARS FOR IMMUNOCHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA (FL) - UPDATE OF THE OSHO#39 TRIAL

被引：0
|
作者：
Herold, M. [1 ]
Maschmeyer, G. [2 ]
Lakner, V. [3 ]
Doelken, G. [4 ]
Ehninger, G. [5 ]
Haenel, M. [6 ]
Hochhaus, A. [7 ]
Rohrberg, R. [8 ]
Neubauer, A. [9 ]
Fischer, L. [10 ]
Al-Ali, H. [11 ]
Wussling, M. [12 ]
Haehling, D. [13 ]
Hahnfeld, S. [14 ]
Hoffmann, F. A. [15 ]
Kahl, C. [16 ]
机构：
[1] HELIOS Klinikum Erfurt, Med Klin 4, Erfurt, Germany
[2] Klinikum Ernst von Bergmann, Potsdam, Germany
[3] Onkol Schwerpunktpraxis, Hamatol, Rostock, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany
[5] Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany
[6] Klinikum Chemnitz, Innere Med Klin, Chemnitz, Germany
[7] Univ Jena, Jena, Germany
[8] Schwerpunktpraxis, Onkol, Halle, Germany
[9] Univ Klinikum, Marburg, Germany
[10] Charite Campus Benjamin Franklin, Med Klin 3, Berlin, Germany
[11] Univ Leipzig, Leipzig, Germany
[12] Schwerpunktpraxis, Onkol, Nordhausen, Germany
[13] HELIOS Klinikum Schwerin, Schwerin, Germany
[14] Schwerpunktpraxis, Onkol, Jena, Germany
[15] Schwerpunktpraxis, Onkol, Leipzig, Germany
[16] Stadt Klinikum, Magdeburg, Germany
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 17 条
  • [1] SUSTAINED SURVIVAL ADVANTAGE AFTER A MEDIAN FOLLOW-UP OF 5 YEARS FOR IMMUNO-CHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA - UPDATE OF THE OSHO#39 TRIAL
    Herold, M.
    Maschmeyer, G.
    Lakner, V.
    Doelken, G.
    Ehninger, G.
    Haenel, M.
    Rohrberg, R.
    Hochhaus, A.
    Neubauer, A.
    Fischer, L.
    von Gruenhagen, U.
    Hahnfeld, S.
    Hoffmann, F.
    Wussling, M.
    Stein, W.
    Kettner, E.
    Haehling, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 239 - 239
  • [2] Survival advantage for immunochemotherapy (R-MCP) over chemotherapy (MCP) alone in advanced follicular lymphoma after a median follow up of 5 years - updated results of the OSHO#39 study
    Herold, M.
    Maschmeyer, G.
    Lakner, V
    Doelken, G.
    Ehninger, G.
    Haenel, M.
    Rohrberg, R.
    ONKOLOGIE, 2010, 33 : 132 - 132
  • [3] Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone -: 50 months up date of the OSHO phase III study (OSHO#39)
    Herold, M.
    Haas, A.
    Doerken, B.
    Neser, S.
    Al Ali, K. H.
    Neubauer, A.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 85
  • [4] Immunochemotherapy (R-MCP) is not superior to chemotherapy (MCP) alone in advanced mantle cell lymphoma - 42 months follow up results of the OSHO 39 study
    Herold, Michael
    Haas, Antje
    Stock, Stephanie
    Neser, Sabine
    Al Ali, Kathrin H.
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Fietz, Thomas
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Mohren, Martin
    Ittel, Thomas H.
    Kettner, Erika
    BLOOD, 2007, 110 (11) : 189B - 189B
  • [5] Immunochemotherapy (R-MCP) prolongs survival in advanced follicular lymphoma -: 50 months up-date of a phase III study of the east German study group hematology and oncology (OSHO#39)
    Herold, M.
    Haas, A.
    Doerken, B.
    Neser, S.
    Al Ali, K. H.
    Neubauer, A.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 180 - 181
  • [6] Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma -: Results of a phase III study (OSHO39)
    Herold, M
    Pasold, R
    Srock, S
    Neser, S
    Niederwieser, D
    Neubauer, A
    Dölken, G
    Naumann, R
    Fietz, T
    Knauf, W
    Freund, M
    Rohrberg, R
    Höffken, K
    Franke, A
    Ittel, TH
    Kettner, E
    Haak, U
    Mey, U
    Klinkenstein, C
    Assmann, M
    von Grünhagen, U
    Dachselt, K
    Schwenke, H
    Bleyl, D
    Wolf, H
    Hahnfeld, S
    Hoffmann, FA
    Lakner, V
    Richter, P
    Hähling, D
    Wolf, HH
    Eschenburg, H
    Clemens, MR
    Grobe, N
    Behringer, D
    ANNALS OF ONCOLOGY, 2005, 16 : 51 - 52
  • [7] Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO
    Herold, M.
    Hoster, E.
    Unterhalt, M.
    Haenel, M.
    Prange-Krex, G.
    Forstpointner, R.
    Florschuetz, A.
    Graeven, U.
    Frickhofen, N.
    Wulf, G.
    Lengfelder, E.
    Lerchenmller, C.
    Schlag, R.
    Dierlamm, J.
    von Weikersthal, Fischer L.
    Ahmed, A.
    Harich, H. -D.
    Rosenwald, A.
    Klapper, W.
    Dreyling, M.
    Hiddemann, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 74 - 74
  • [8] Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the east German study group hematology and oncology (OSHO#39).
    Herold, Michael
    Haas, Antje
    Srock, Stephanie
    Neser, Sabine
    Al Ali, Kathrin H.
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Fietz, Thomas
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Franke, Astrid
    Ittel, Thomas H.
    Kettner, Erika
    BLOOD, 2006, 108 (11) : 147A - 147A
  • [9] Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
    Hirt, Carsten
    Hoster, Eva
    Unterhalt, Michael
    Haenel, Mathias
    Prange-Krex, Gabriele
    Forstpointner, Roswitha
    Florschuetz, Axel
    Graeven, Ullrich
    Frickhofen, Norbert
    Wulf, Gerald
    Lengfelder, Eva
    Lerchenmueller, Christian
    Schlag, Rudolf
    Dierlamm, Judith
    von Weikersthal, Ludwig Fischer
    Ahmed, Asima
    Harich, Hanns-Detlev
    Rosenwald, Andreas
    Klapper, Wolfram
    Dreyling, Martin
    Hiddemann, Wolfgang
    Herold, Michael
    HEMASPHERE, 2021, 5 (07):
  • [10] Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
    Provencio, Mariano
    Franco, Fernando
    Gomez-Codina, Jose
    Quero Blanco, Cristina
    Llanos, Marta
    Garcia-Arroyo, Francisco
    de la Cruz, Luis
    Guma, Josep
    Ramon Delgado, Juan
    Alvarez, Ruth
    Ignacio Chacon, Jose
    Royuela, Ana
    Rueda, Antonio
    LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 856 - 859
12